Avaliação ecotoxicológica da água e do sedimento do rio Corumbataí, SP

The Corumbataí River drains an economically important area which is mainly represented by the municipalities of Piracicaba and Rio Claro. In view of the impacts caused by the discharge of industrial waste and domestic sewage into the Piracicaba River, the Corumbataí has become increasingly significant as a source of water for the municipality of Piracicaba. However, chemical, physical, and microbiological analyses carried out prior to the present study had already indicated a decline in the quality of the Corumbataí waters. This study aimed to assess, through water and sediment samples, both acute and chronic toxicity to Daphnia magna and Daphnia similis, and to analyze acid-volatile sulfide (AVS) and simultaneously extracted metal (SEM) in the sediment. Resulting data were intended to be a contribution to future projects for the management and recuperation of this system. To that aim, water and sediment were collected at seven Corumbataí sampling stations in November 2003 and March 2004. Acute toxicity to D. similis was detected in water and sediment samples from the Piracicaba station, located at the mouth of the Corumbataí River. Chronic toxicity was identified in the water or sediment samples of all stations, with the exception of Analândia Montante (upstream), at the head of the river. This was found to affect survival, growth, and fecundity of the test-organisms. The AVS and SEM analyses showed the bioavailability of the metals, thus explaining toxicity found in bioassaying samples of water and sediment. The use of two test-organism species made it possible to obtain a better assessment of the condition of both water and sediment samples of the Corumbataí River.O rio Corumbataí drena uma área de importância econômica representada principalmente pelos municípios de Piracicaba e Rio Claro. Face aos impactos causados pelos lançamentos de efluentes industriais e domésticos no rio Piracicaba, o rio Corumbataí assumiu importância para o abastecimento do município de Piracicaba. Entretanto, análises químicas, físicas e microbiológicas realizadas no rio Corumbataí anteriormente a este estudo, indicaram a queda da qualidade de suas águas. Os objetivos deste estudo foram a avaliação da toxicidade aguda e da toxicidade crônica das amostras de água e sedimento, para Daphnia magna e Daphnia similis, e a análise do sulfeto volatilizável por acidificação (SVA) e dos metais simultaneamente extraídos do sedimento (MSE), no sentido de fornecer dados que possam contribuir com projetos futuros de manejo e recuperação desse sistema. Para tanto, água e sedimento provenientes de sete estações de coleta do rio Corumbataí foram coletados em novembro de 2003 e março de 2004. Foi detectada toxicidade aguda para D. similis das amostras de água e sedimento da estação Piracicaba, na foz do rio Corumbataí. A toxicidade crônica foi identificada na água ou no sedimento de todas as estações de coleta, exceto Analândia Montante (nascente do rio), influenciando a sobrevivência, crescimento e fecundidade dos organismos-teste. As análises do SVA e MSE revelaram a biodisponibilidade dos metais, explicando a toxicidade das amostras de água e de sedimento encontrada nos bioensaios. A adoção de duas espécies de organismos-teste possibilitou uma melhor avaliação dos compartimentos amostrados.(FAPESP) São Paulo Research Foundatio

El libro y la lectura en los recintos penitenciarios de la región de Valparaíso

Experiences and reflection about reading in prison and prison libraries. The book results from a project directed by academic researchers of the University of Playa Ancha and collects texts from Chile and from international experiences. It departs from actions led by the Biblioredes Program of Chile, aimed at establishing a virtuous relation with the quality of life inside the prison and social reinsertion processes

El libro y la lectura en los recintos penitenciarios de la región de Valparaíso

Experiences and reflection about reading in prison and prison libraries. The book results from a project directed by academic researchers of the University of Playa Ancha and collects texts from Chile and from international experiences. It departs from actions led by the Biblioredes Program of Chile, aimed at establishing a virtuous relation with the quality of life inside the prison and social reinsertion processes

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline